Nature

Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma

Aims To compare the diurnal intraocular pressure (IOP) efficacy and safety of timolol vslatanoprost in subjects with exfoliation glaucoma (XFG). Methods A 3-month prospective, single-masked, ...
Medical News Today

Latanoprost and cost

Latanoprost is a generic prescription medication. The Food and Drug Administration (FDA) has approved it to treat increased pressure in the eyes. The drug is for use in adults who have either ...
Business Wire

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results

IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ...
KLFY News 10

TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)

TC-002 is the first of four proprietary glaucoma drugs in the TearClear near term pipeline CHICAGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- TearClear, an ophthalmic pharmaceutical company that transforms ...
Yahoo

More than 3 million bottles of eye drops recalled over safety concerns, FDA says

Add Yahoo as a preferred source to see more of our stories on Google. Man drops eye drops install lenses, moisturizing. Preservation and solution vision problems. Eye diseases are recognized. Drops ...
Business Wire

Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%

In September 2016, the Company reported the successful topline efficacy results from the first Phase 3 registration trial for Roclatan™ ophthalmic solution, “Mercury 1,” which achieved its primary ...